News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Clash Between Company and Doc Shake HeartWare (HTWR) Shares


8/26/2013 8:57:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Comments made by HeartWare CEO Doug Godshall seem to be in conflict with those of principal ENDURANCE trial investigator Dr. Joseph Rogers, putting analysts on edge. Shares of HeartWare International (NSDQ:HTWR) are on watch in the wake of negative commentary from a Northland Capital Markets analyst. Analyst Suraj Kalia cited "glaring inconsistencies" between statements made by a principal investigator for HeartWare International's pivotal ENDURANCE trial for the company's ventricular-assist device (VAD) as destination therapy and recent remarks made by the HeartWare CEO Doug Godshall on calls with financial analysts.

Help employers find you! Check out all the jobs and post your resume.

Read at MassDevice
Read at Street Insider

comments powered by Disqus
HeartWare
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES